1 / 21

PC Enzinger, BA Burtness, DR Hollis, D Niedzwiecki, DH Ilson, AB Benson 3rd,

CALGB 80403 / ECOG 1206: Randomized Phase II Study of Standard Chemotherapy + Cetuximab for Metastatic Esophageal Cancer. PC Enzinger, BA Burtness, DR Hollis, D Niedzwiecki, DH Ilson, AB Benson 3rd, RJ Mayer, RM Goldberg. CALGB 80403 / ECOG E1206: Background.

kelii
Download Presentation

PC Enzinger, BA Burtness, DR Hollis, D Niedzwiecki, DH Ilson, AB Benson 3rd,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CALGB 80403 / ECOG 1206: Randomized Phase II Study of Standard Chemotherapy + Cetuximab for Metastatic Esophageal Cancer PC Enzinger, BA Burtness, DR Hollis, D Niedzwiecki, DH Ilson, AB Benson 3rd, RJ Mayer, RM Goldberg

  2. CALGB 80403 / ECOG E1206: Background • NCI-sponsored Esophageal Cancer Strategy Meeting of the GI Intergroup: • No superior regimen or molecularly targeted agent for esophagogastric cancer. • Randomized Phase II. • Response rate is primary endpoint - fastest. • Best regimen  phase III vs best “standard”.

  3. CALGB 80403 / ECOG E1206: Background

  4. CALGB 80403 / ECOG E1206: Background • Cetuximab: chimerized monoclonal antibody - EGFR (oropharyngeal cancer , NSCLC, and colorectal cancer) • EGFR expression – 3/4 of ADC and SCC 1-5 • EGFR expression correlates with prognosis in esophagogastric ADC and SCC 1-5 • KRAS mutations occur in approx. 2% of esophageal cancers6 1-5 Mukaida. Cancer 1991; Itakura. Cancer 1994; Yacoub. Mod Pathol 1997; Torzewski. Anticancer Res 1997; Koyama. J Cancer Res Clin Oncol 1999; 6 Lea. Carcinogenesis 2007

  5. CALGB 80403 / ECOG E1206: Statistics • Response Rate: met esophageal ADC (cisplatin/ 5-FU) is approx. 25% in randomized trials. • Simon’s Optimal Two-Stage Design • Null Hypothesis vs. Alternative Hypothesis • RR = 0.25 vs. RR = 0.40 • Regimen is efficacious if 21+ responses among 64 patients treated in each arm. • Power: 90% Significance Level: 0.1

  6. CALGB 80403 / ECOG E1206: Eligibility • Metastatic ADC or SCC of the esophagus or GE junction (Siewert AEG Type I-II). • Measurable disease required. • No prior chemotherapy, radiotherapy, or therapy that targets the EGFR pathway. • ECOG PS 0-2. • Adequate total caloric intake to maintain body weight. • No ≥ grade 2 peripheral neuropathy or ≥ grade 2 diarrhea.

  7. CALGB 80403 / ECOG E1206: Schema ARM A: (ECF + cetuximab); 1 cycle = 21 days Cetuximab 400  250mg/m2 IV, weekly Epirubicin 50 mg/m2 IV, day 1 Cisplatin 60mg/m2 IV, day 1 Fluorouracil 200mg/m2/day, days 1-21 ARM B: (IC + cetuximab); 1 cycle = 21 days Cetuximab 400  250mg/m2 IV, weekly Cisplatin 30 mg/m2 IV, days 1 and 8 Irinotecan 65 mg/m2 IV, days 1 and 8 Stratification: ECOG 0-1 vs 2 ADC vs. SCC ARM C: (FOLFOX + cetuximab); 1 cycle = 14 days Cetuximab 400  250mg/m2 IV, weekly Oxaliplatin 85 mg/m2 IV, day 1 Leucovorin 400 mg/m2, day 1 Fluorouracil 400 mg/m2 IV bolus, day 1 Fluorouracil 2400 mg/m2 IV over 46hrs (days 1-2)

  8. CALGB 80403/ECOG 1206: Consort Diagram September 2006 to May 2009

  9. CALGB 80403 / ECOG E1206: Patient Characteristics *No locally advanced *7 cases post esophagectomy

  10. CALGB 80403/ECOG 1206: Response *RECIST - confirmed; restaging every 6 weeks

  11. CALGB 80403/ECOG 1206: Survival

  12. CALGB 80403/ECOG 1206: Overall Survival by Arm

  13. CALGB 80403/ECOG 1206: Progression-Free Survival by Arm

  14. ECF ECF - - C C IC IC - - C C FOLFOX FOLFOX - - C C Hematologic Hematologic 49% 49% 58% 58% 46% 46% Neutropenia Neutropenia 48% 48% 49% 49% 42% 42% Leukocytopenia Leukocytopenia 7% 7% 21% 21% 13% 13% Anemia Anemia 4% 4% 13% 13% 6% 6% Thrombocytopenia Thrombocytopenia 4% 4% 8% 8% 1% 1% CALGB 80403/ECOG 1206: Grade 3-4 Heme Toxicity* P = NS for all comparisons *No grade 5 hematologic toxicity

  15. P - value p=0.03 p=0.03 p=0.05 p=0.05 p=0.06 p=0.06 4% 17% 17% Pain Pain 9% 9% 1% 1% 3% 3% Pulmonary Pulmonary 4% 4% 1% 1% † † 0% 0% Vascular Vascular 6% 6% 7% 7% 4% 4% p=0.01 Death; no CTCAE defined Death; no CTCAE defined 6% 6% 0% 0% 0% 0% Total ( Total ( Heme Heme + Non + Non - - Heme Heme ) ) 75% 75% 86% 86% 79% 79% CALGB 80403/ECOG 1206: Grade 3-5 Non-Heme Toxicity P - value ECF ECF - - C C IC IC - - C C FOLFOX FOLFOX - - C C Non Non - - Hematologic Hematologic 66%* 66%* 77%** 77%** 65% 65% Constitutional symptoms Constitutional symptoms 13% 13% 18% 18% 17% 17% Dermatologic Dermatologic 16% 16% 11% 11% 19% 19% † † Gastrointestinal Gastrointestinal 28% 28% 42% 42% 22% 22% Infection Infection 13% 13% 8% 8% 7% 7% Metabolic Metabolic 16% 16% 34% 34% 22% 22% Neurologic Neurologic 12% 12% 4% p=0.01 * Includes 4 deaths ** Includes 2 deaths † Indicates a death P = NS except as noted

  16. CALGB 80403/ECOG 1206: Tolerability

  17. CALGB 80403/ECOG 1206: Discussion Is there a signal for cetuximab in esophageal cancer? 15% -10% Vs. 2.5mo -2mo *Lorenzen. Ann Oncol 2009

  18. CALGB 80403/ECOG 1206: Discussion Is there a signal for EGFR antibodies in esophagogastric cancer? EOX REAL 3* EOX + Panitumumab Cape / Cis EXPAND** Cape / Cis + Cetuximab * http://clinicaltrials.gov/ct2/show/NCT00824785 **http://clinicaltrials.gov/ct2/show/NCT00678535

  19. CALGB 80403/ECOG 1206: Conclusions • Primary endpoint: all 3 regimens > 40% RR • IC-C: appeared to have lowest response and survival & most adverse events. • ECF-C: appeared to have highest response, but highest treatment-related mortality and most treatment-related modifications. • FOLFOX-C: good response and survival and best tolerated – best for phase III development.

  20. AcknowledgementsThank you to the 245 patients and all the investigators who participated at the following sites: Supported by CA314946, Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis

  21. Thank You!

More Related